Futures Mixed Ahead...
Health Care: Drugs
Venaxis Inc (APPY: NASDAQ)
$1.32 0.05 | 3.94%
06/18/13 - 04:00 PM ET
Growth Rates
| GROWTH RATES |
|---|
| REVENUE (Trailing 12 Quarters) |
| EARNINGS PER SHARE (Trailing 12 Quarters) |
| DIVIDENDS (Trailing 12 Quarters) |
Portfolios with APPY
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- UserSUPRATRADE-2709091838
- UserBrahmsian's Debt/Equity Por...
- UserBrahmsian's Financially Sou...
- Userdan vosika Portfolio 1
- Usergame on
Latest APPY Headlines from TheStreet
- 3 Stocks Under $10 Making Big Moves 05.31.13 | 02:05 pm
- 5 Biotech Stocks Under $10 Moving Higher 01.30.13 | 08:01 am
- 5 Breakout Stocks: Must-See Charts 12.21.12 | 05:12 pm
- 5 Stocks Under $10 Set to Soar Higher 09.27.12 | 01:09 pm
- 4 Biotech Stocks Under $10 Making Big Moves 09.11.12 | 02:09 pm
- Biotech Sector Weekly Rewind 11.13.10 | 07:11 am
- Vantage Drilling, First M&F: Volume Movers 07.20.10 | 07:07 am
- AspenBio Finds Fault Afar for Failure 07.20.10 | 06:07 am
- Biotech Stock Mailbag: Spectrum Pharma 06.18.10 | 07:06 am
- Hellenic Telecom, AspenBio Pharma: Midday Volume Plays 06.07.10 | 12:06 pm
Press Releases for APPY
- JAMA Pediatrics Study Highlights Cancer Risk Associated With CT Scans - PR Newswire 06.13.13 | 07:06 am
- Venaxis Closes Underwritten Public Offering, Including Full Over-Allotment - PR Newswire 05.30.13 | 04:05 pm
- Venaxis Announces Pricing Of Offering Of Common Stock And Warrants - PR Newswire 05.23.13 | 07:05 pm
- Venaxis Appoints SomaLogic CMO And Former Pfizer Executive Stephen A. Williams, M.D., Ph.D., To Board Of Directors - PR Newswire 04.18.13 | 04:04 pm
- Venaxis Advances Pivotal U.S. Study And Accelerates European Market Development For APPY1 Blood-based Appendicitis Test - PR Newswire 03.26.13 | 04:03 pm
- Venaxis To Provide Fourth Quarter 2012 Business Update - PR Newswire 03.19.13 | 07:03 am
- Venaxis Secures Additional European Commercial Development Agreements For APPY1 - PR Newswire 03.18.13 | 07:03 am
- Venaxis To Present At 25th Annual ROTH Conference - PR Newswire 03.11.13 | 04:03 pm
- Venaxis Executes First Commercial Development Agreement And Receives Purchase Order From EMELCA Bioscience For Initial EU Launch - PR Newswire 02.07.13 | 07:02 am
- Venaxis Initiates Patient Enrollment For APPY1 Pivotal Study - PR Newswire 01.15.13 | 07:01 am
Partner Headlines for APPY
- Weekly CFO Buys Highlight: CPRX, APPY, MEI, MNKD - GuruFocus 07.09.12 | 01:07 pm
- Weekly Market Wrap: Markets SHAKE, Microsoft's NEW Product, Bank Ratings SLASHED - Wall St. Cheat Sheet 06.23.12 | 09:06 am
- P&G SHAVES Profit Outlook and 4 Hot Stocks to Watch - Wall St. Cheat Sheet 06.20.12 | 12:06 pm
- Market Wrap: Oil SPILLS Lower, Microsoft RALLIES, Operation TWIST - Wall St. Cheat Sheet 06.20.12 | 10:06 am
- Morning Market Losers - Benzinga 06.20.12 | 09:06 am
- Ultimate Market Recap: Iffy Adobe Guidance, Jabil Jumps 7% - Wall St. Cheat Sheet 06.20.12 | 08:06 am
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 06.19.12 | 09:06 am
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 06.05.12 | 09:06 am
- Morning Market Losers - Benzinga 12.19.11 | 09:12 am
- AspenBio Pharma Reports AppyScore(TM) ELISA-Based Pivotal Trial Results and Outlines Plans for AppyScore Cassette-Based Test - Benzinga 07.19.10 | 04:07 pm
